Shots:
- The first healthy volunteer has been dosed in a P-I study of GRAd-COV2 against COVID-19 which is conducted by the Lazzaro Spallanzani National Institute for Infectious Diseases under the sponsorship of ReiThera
- The P-I study will evaluate the safety & immunogenicity of GRAd-COV2 in 90 healthy volunteers divided equally into two age cohorts: 18-55yrs. and 65-85yrs. with participants to be monitored over a 24wks. period. The P-I study will also evaluate vaccine dose for further investigation in a P-II/III trial
- ReiThera is expecting the results of interim safety and immunogenicity analysis by mid Q4’20 which will guide dose selection for P-II/III trial. The company plans to commence international P-II/III in countries with high rates of SARS-CoV-2 infection by the end of 2020, post-P-I outcomes
Click here to read full press release/ article | Ref: PRNewswire | Image: Global Times
